GKOS (US) share price forecast & AI signal — Glaukos Corporation
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in GKOS
Glaukos Corporation is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a BUY with low confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $224.41 |
| 2026-11-05 | $219.98 |
| 2026-11-04 | $246.70 |
| 2026-11-03 | $233.04 |
| 2026-11-02 | $238.61 |
| 2026-10-30 | $237.60 |
| 2026-10-29 | $242.48 |
GKOS FAQ
Is Glaukos Corporation (GKOS) a buy or sell this week?
The ACE Stock Bots machine-learning model rates GKOS a BUY for the week of 2026-10-30 with low confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for GKOS?
Every week the model scores GKOS across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.